Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis.
about
Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugatesSearching for the human genetic factors standing in the way of universally effective vaccinesKinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial.Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.Haemophilus influenzae type b conjugate vaccines.Assessing efficacy of Haemophilus influenzae type b combination vaccines.Evaluating the immune response to combination vaccines.Manufacturing issues related to combining different antigens: an industry perspective.Combination vaccines: choices or chaos? A practitioner's perspective.Impaired haemophilus influenzae type b transplacental antibody transmission and declining antibody avidity through the first year of life represent potential vulnerabilities for HIV-exposed but -uninfected infants.The UK Hib vaccine experienceFast, antigen-saving multiplex immunoassay to determine levels and avidity of mouse serum antibodies to pertussis, diphtheria, and tetanus antigens.Hib vaccination in infants born prematurely.Combination vaccines against diarrheal diseases.Haemophilus influenzae type b reemergence after combination immunization.PEDIARIX: clinical trials.New combination vaccines still need a boost.Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of ageA combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine.Combination conjugate vaccines.Anti-polyribosylribitol phosphate antibody concentrations and avidities in children since the start of Haemophilus influenzae type b immunization of infants in the United KingdomThe Immunogenicity and Safety of a Combined DTaP-IPV//Hib Vaccine Compared with Individual DTaP-IPV and Hib (PRP~T) Vaccines: a Randomized Clinical Trial in South Korean Infants.Neonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines.Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine.Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine).Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components.The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity.Glycoconjugate vaccines.Review of a new fully liquid, hexavalent vaccine: Hexaxim.Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience.DTaP5-IPV-Hib-HepB, a hexavalent vaccine for infants and toddlers.Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, contrHaemophilus influenzae type b vaccine--booster campaignQuality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines.Conjugate vaccines.A review of Haemophilus influenzae disease in Europe from 2000-2014: challenges, successes and the contribution of hexavalent combination vaccines.Understanding the impact of Hib conjugate vaccine on transmission, immunity and disease in the United Kingdom.Immunogenicity and reactogenicity of DTPw-HB/Hib vaccine administered to colombian infants after a birth dose of hepatitis B vaccine.Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations i
P2860
Q24514532-0222E077-88D5-4629-8E01-CAEE7A928514Q27007034-FC4EB5FD-40F5-4A8E-9FF4-811CF9455A48Q33557154-224617A2-78B3-4578-AD06-CC07EA5CDDF1Q34006352-9AD6D916-E4D0-46C4-BF1A-6546CAB113F1Q34349892-5C095708-2105-44C5-8D52-CCF5919B458CQ34440105-0E43458C-0016-4D35-8812-03B106488BFAQ34440112-3DACAD2C-1FEC-47C6-A162-779672349D14Q34440161-795A9469-F0A7-4AFE-BB42-2D9B0C707008Q34440194-52E9BC4E-2961-4209-9F9A-3F097A039F1AQ34593078-6D4E9218-3AAB-4C06-8D9A-5F07E01F50BEQ34649094-AA286B12-D883-4B85-8D10-F2C246DF1D34Q35066267-7B514986-6A98-4A92-A772-7A954B951BE0Q35275707-935953A9-43DD-49AB-9B03-FF49666DB036Q35896237-CA4F09A7-A1FB-4F60-97D5-17125FD27C2AQ36026108-C0864525-8BEB-4EE5-A7BE-F350D51CE1CAQ36124930-354DAEDC-DA6A-45CE-9C47-0F9409DF8E2EQ36153895-1129EDD4-4D5B-4A60-B00D-185719FA4D62Q36153910-835D3D2C-110B-405F-9800-356AE106E861Q36350547-10627EFC-C6C2-42E1-B3C7-445D14B6CFF3Q36446881-CDB52547-B8D0-473D-8DC1-5277A959B74AQ37099250-0CCF4173-C20A-4EFD-A6B0-C0200521A229Q37153176-1FCBD642-1F64-4035-B13E-2A716A7D5BBEQ37282316-639FBA67-10FB-47F4-B255-37AA291A11D8Q37325678-6A6B577D-D59C-4F14-85D0-95E14E13D3A3Q37503223-1526C0A0-9FBC-4C9A-B643-4D540CE87D80Q37521333-B4C9FFC7-D75C-4A7B-B1BF-E571B143858BQ37621061-1BD946AE-168C-4188-955C-5CE220DC626BQ38044755-7F128BDF-AC50-4409-BF1E-C30589E404F4Q38084695-5A953902-8670-4DE7-99D3-1E8BD3510D64Q38367830-FBE92635-63A0-45E5-B97B-BF4FED5F2C41Q40075871-F4B2E202-0C74-43E5-838F-9D05C3D0BA08Q40285504-C41D4291-EEBF-4595-A5D0-E0C8415DCBBAQ42783248-BA20EACC-143A-49DB-9E39-45BF2F2FF340Q42909238-AC29E55B-A1FC-464C-961D-B920AF2AC2A4Q43098481-B2EFAAFE-7FA2-49E4-8EAE-286E289FA944Q47877094-0E03D45E-9F8E-4ADF-A385-A1E1B429E78EQ51908614-464F6154-A236-48FB-9850-329A8B3BF2DCQ53856373-E859B895-13B3-4F6B-A695-EA80C7D4D836Q58476748-479176D2-04E1-419F-A60D-0DA6A6CA77BA
P2860
Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis.
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Combined vaccination of Haemop ...... ontaining acellular pertussis.
@ast
Combined vaccination of Haemop ...... ontaining acellular pertussis.
@en
type
label
Combined vaccination of Haemop ...... ontaining acellular pertussis.
@ast
Combined vaccination of Haemop ...... ontaining acellular pertussis.
@en
prefLabel
Combined vaccination of Haemop ...... ontaining acellular pertussis.
@ast
Combined vaccination of Haemop ...... ontaining acellular pertussis.
@en
P2093
P1433
P1476
Combined vaccination of Haemop ...... ontaining acellular pertussis.
@en
P2093
P304
P356
10.1016/S0140-6736(99)04377-9
P407
P577
1999-12-01T00:00:00Z